These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38309499)

  • 1. Age dependent discrepancy between SARS-CoV-2 anti-nucleoprotein antibody and anti-RBD spike protein antibody in children reflects vaccine coverage.
    Fujii Y; Ishigaki H; Miyairi I; Niizeki N; Nagura O; Yamashita K; Maekawa M; Furuhashi K
    J Infect Chemother; 2024 Jul; 30(7):646-650. PubMed ID: 38309499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies.
    Fenwick C; Croxatto A; Coste AT; Pojer F; André C; Pellaton C; Farina A; Campos J; Hacker D; Lau K; Bosch BJ; Gonseth Nussle S; Bochud M; D'Acremont V; Trono D; Greub G; Pantaleo G
    J Virol; 2021 Jan; 95(3):. PubMed ID: 33144321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the SARS-CoV-2 antibody landscape in Norway in the late summer of 2022: high seroprevalence in all age groups with patterns of primary Omicron infection in children and hybrid immunity in adults.
    Tunheim G; Fossum E; Robertson AH; Rø GØI; Chopra A; Vaage JT; Vikse EL; Kran AB; Magnus P; Trogstad L; Mjaaland S; Hungnes O; Lund-Johansen F
    BMC Infect Dis; 2024 Aug; 24(1):841. PubMed ID: 39164637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence, Japan, 2023.
    Kinoshita R; Miyamoto S; Sakuraba S; Sugihara J; Suzuki M; Suzuki T; Yoneoka D
    Emerg Infect Dis; 2024 Jun; 30(6):1267-1270. PubMed ID: 38782366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Saliva SARS-CoV-2 Antibody Prevalence in Children.
    Keuning MW; Grobben M; de Groen AC; Berman-de Jong EP; Bijlsma MW; Cohen S; Felderhof M; de Groof F; Molanus D; Oeij N; Rijpert M; van Eijk HWM; Koen G; van der Straten K; Oomen M; Visser R; Linty F; Steenhuis M; Vidarsson G; Rispens T; Plötz FB; van Gils MJ; Pajkrt D
    Microbiol Spectr; 2021 Oct; 9(2):e0073121. PubMed ID: 34523985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term immune response to SARS-CoV-2 infection and vaccination in children and adolescents.
    Messiah SE; Talebi Y; Swartz MD; Sabharwal R; Han H; Bergqvist E; Kohl HW; Valerio-Shewmaker M; DeSantis SM; Yaseen A; Kelder SH; Ross J; Padilla LN; Gonzalez MO; Wu L; Lakey D; Shuford JA; Pont SJ; Boerwinkle E
    Pediatr Res; 2024 Jul; 96(2):525-534. PubMed ID: 37875728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C).
    Rostad CA; Chahroudi A; Mantus G; Lapp SA; Teherani M; Macoy L; Tarquinio KM; Basu RK; Kao C; Linam WM; Zimmerman MG; Shi PY; Menachery VD; Oster ME; Edupuganti S; Anderson EJ; Suthar MS; Wrammert J; Jaggi P
    Pediatrics; 2020 Dec; 146(6):. PubMed ID: 32879033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Anti-SARS-CoV-2-Specific Antibody Signatures in Maternal and Infant Blood after COVID-19 Infection versus COVID-19 Vaccination during Pregnancy.
    Sabharwal V; Taglauer E; Demos R; Snyder-Cappione J; Shaik-Dasthagirisaheb YB; Parker-Kelleher S; Hunnewell J; Boateng J; Clarke K; Yuen R; Barnett ED; Wachman EM; Yarrington CD
    Am J Perinatol; 2024 May; 41(S 01):e2970-e2977. PubMed ID: 37774748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seroprevalence of SARS-CoV-2 in self-reported COVID-19-free children.
    Huang HL; Lu CY; Liu YC; Chang TH; Yen TY; Huang KA; Tang HJ; Chang LY; Huang LM
    J Microbiol Immunol Infect; 2024 Aug; 57(4):546-553. PubMed ID: 38777654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.
    Gallais F; Gantner P; Bruel T; Velay A; Planas D; Wendling MJ; Bayer S; Solis M; Laugel E; Reix N; Schneider A; Glady L; Panaget B; Collongues N; Partisani M; Lessinger JM; Fontanet A; Rey D; Hansmann Y; Kling-Pillitteri L; Schwartz O; De Sèze J; Meyer N; Gonzalez M; Schmidt-Mutter C; Fafi-Kremer S
    EBioMedicine; 2021 Sep; 71():103561. PubMed ID: 34455390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 anti-RBD and anti-N protein responses are differentially regulated between mother-child pairs: insight from a national study cohort at the Faroe Islands.
    Jarlhelt I; Hansen CB; Pérez-Alós L; Weihe P; Petersen MS; Garred P
    Front Immunol; 2024; 15():1418678. PubMed ID: 39021574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The seroprevalence of SARS-CoV-2-specific antibodies in Australian children: A cross-sectional study.
    Koirala A; McRae J; Britton PN; Downes M; Prasad SA; Nicholson S; Winkler NE; O'Sullivan MVN; Gondalwala F; Castellano C; Carey E; Hendry A; Crawford N; Wadia U; Richmond P; Marshall HS; Clark JE; Francis JR; Carr J; Bartlett A; McMullan B; Skowno J; Hannah D; Davidson A; von Ungern-Sternberg BS; Lee-Archer P; Burgoyne LL; Waugh EB; Carlin JB; Naing Z; Kerly N; McMinn A; Hunter G; Heath C; D'Angelo N; Finucane C; Francis LA; Dougherty S; Rawlinson W; Karapanagiotidis T; Cain N; Brizuela R; Blyth CC; Wood N; Macartney K
    PLoS One; 2024; 19(9):e0300555. PubMed ID: 39292730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serological response in health care workers after a single dose of SARS-CoV-2 vaccine using six automated SARS-CoV-2 antibody assays.
    Cuykx M; Mortelé O; Jansens H; Schouwers S; Meskal A; Hoffbauer I; Peeters B
    Diagn Microbiol Infect Dis; 2021 Oct; 101(2):115486. PubMed ID: 34332306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China.
    Feng X; Yin J; Zhang J; Hu Y; Ouyang Y; Qiao S; Zhao H; Zhang T; Li X; Zhang L; Zhang J; Jin R; Feng Y; Su B
    Front Immunol; 2021; 12():614436. PubMed ID: 33790892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.
    Xu QY; Xue JH; Xiao Y; Jia ZJ; Wu MJ; Liu YY; Li WL; Liang XM; Yang TC
    Front Immunol; 2021; 12():786554. PubMed ID: 35003104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating anti-SARS-CoV-2 nucleocapsid (N)-protein antibodies and anti-SARS-CoV-2 spike (S)-protein antibodies in an African setting: herd immunity, not there yet!
    Mveang Nzoghe A; Leboueny M; Kuissi Kamgaing E; Maloupazoa Siawaya AC; Bongho EC; Mvoundza Ndjindji O; Padzys GS; Ndeboko B; Ategbo S; Djoba Siawaya JF
    BMC Res Notes; 2021 Apr; 14(1):152. PubMed ID: 33879229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of IgG antibodies against the receptor binding domain of the spike protein and nucleocapsid of SARS-CoV-2 at university students from Southern Mexico: a cross-sectional study.
    Bailón-Cuenca JA; Cortés-Sarabia K; Legorreta-Soberanis J; Alvarado-Castro VM; Juárez-Baltazar U; Sánchez-Gervacio BM; Vences-Velázquez A; Leyva-Vázquez MA; Del Moral-Hernández O; Illades-Aguiar B
    BMC Infect Dis; 2024 Jun; 24(1):584. PubMed ID: 38867165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Humoral Immune Response against SARS-CoV-2 after Natural Infection and Subsequent Vaccination According to WHO International Binding Antibody Units (BAU/mL).
    Ruetalo N; Flehmig B; Schindler M; Pridzun L; Haage A; Reichenbächer M; Kirchner T; Kirchner T; Klingel K; Ranke MB; Normann A
    Viruses; 2021 Nov; 13(12):. PubMed ID: 34960605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.
    Charlton CL; Nguyen LT; Bailey A; Fenton J; Plitt SS; Marohn C; Lau C; Hinshaw D; Lutsiak C; Simmonds K; Kanji JN; Zelyas N; Lee N; Mengel M; Tipples G
    Microbiol Spectr; 2021 Sep; 9(1):e0029121. PubMed ID: 34406813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.